Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Sunovion announced the launch of Lonhala Magnair (glycopyrrolate) inhalation solution for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Lonhala Magnair, approved in December 2017, is the first nebulized long-acting muscarinic antagonist (LAMA) indicated for COPD. The Magnair Nebulizer System utilizes eFlow technology to deliver the medication via oral inhalation in 2–3 minutes. The portable and closed system nebulizer allows users to breathe normally as they use the device.
Lonhala Magnair is available as a 25mcg strength inhalation solution per 1mL vial. It is supplied as a Starter Kit that includes 60 vials and a complete Magnair Nebulizer System or as a Refill Kit that includes 60 vials and a Magnair replacement handset.
Lonhala vials should only be used with the Magnair Nebulizer System. In addition, the Magnair system should not be used with any other medicine. It is recommended that the Magnair replacement handset parts that come with each Lonhala Magnair refill prescription should always be used.
For more information call (844) 276-8262 or visit LonhalaMagnair.com.
This article originally appeared on MPR
